secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001104659-23-024751
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics enters $200M ATM equity facility, terminates prior $150M ATM
--------------------------------------------------------------------------------

- New Sales Agreement with SVB Securities and Cantor Fitzgerald for up to $200M in common stock at-the-market.
- Prior $150M ATM terminated; $72.7M net proceeds raised from 4.8M shares under prior agreement.
- Commission of 3% of gross proceeds on sales under new agreement.
- Company not obligated to sell any shares; offering at its sole discretion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465923024751/0001104659-23-024751-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465923024751/tm237408d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-024751

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer